45 results on '"Molina-Vila, M.A."'
Search Results
2. Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
3. EP08.02-032 High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
4. EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
5. EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
6. P1.03C.01 A Landscape of the Driver Alterations in 920 Brazilian Lung Cancer Patients
7. 1356P Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
8. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
9. P68.05 Human Lung Carcinoma Primary Cultures From Malignant Pleural Effusions as a Tool for Drug Screening and Personalized Therapy
10. MA03.01 EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer
11. P23.02 Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients
12. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
13. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
14. 2325P Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
15. P60.12 Baseline Tumor Immune Cell Infiltration and Activation can Predict Checkpoint Inhibitor Pneumonitis in Lung Cancer Patients
16. P65.04 Tracking circRNAs in Lung Adenocarcinoma Samples as Promising Biomarkers for Cancer Detection using the NanoString nCounter®
17. FP12.03 SRC-Homology 2 Domain-Containing Phosphatase 2 (SHP2) in Resected Lung Adenocarcinoma (LUAD)
18. P61.01 Imipramine Blue (IP) plus MET Tyrosine Kinase Inhibitors (TKI) Suppress Lung Adenocarcinoma (LUAD) KRAS Mutation Tumor Growth
19. FP03.04 Selinexor can Inhibit Nuclear Export of HMGB1, a Negative Predictive Marker for Immunotherapy Response
20. 199P Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
21. 178P Targeting XPO1-dependent nuclear export of HMGB1 in non-small cell lung cancer
22. 1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
23. 247 (PB027) - Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
24. P2.04-79 High Rate of Immune Related Pneumonitis in Lung Cancer Patients Treated with Anti PD-1 Antibodies
25. Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
26. P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
27. P2.01-56 Copy Number Gains (CNGs) of Clinically Relevant Genes in Advanced NSCLC Patients
28. P1.03-31 BRAF Mutations: Classes I, II and III in NSCLC Patients Included in the SLLIP Trial, Targeted Treatment According to Class
29. P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC
30. P1.01-56 Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
31. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
32. 198TiP Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study
33. Antitumor effects of EGF-pathway immunization in NSCLC
34. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
35. Innate resistance in EGFR mutant non-small cell lung cancer (NSCLC) patients by coactivation of receptor tyrosine kinases (RTKs)
36. 35P - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
37. 149P: The role of CTCs and cfDNA for diagnosis and monitoring of EGFR mutations in advanced NSCLC patients
38. 3120 Analysis of gene expression in the re-replication pathway and selective blockade with checkpoint inhibitors as a therapeutic option in NSCLC
39. 3118 PB1 a new DDR2 inhibitor: Potential treatment to SCC patients
40. 3O - Innate resistance in EGFR mutant non-small cell lung cancer (NSCLC) patients by coactivation of receptor tyrosine kinases (RTKs)
41. 254 Molecular analysis in breast cancer: correlation with Immunohistochemical classification and pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC)
42. 354 PCR-based assay for BRAFV600 mutation analysis in ctDNA: clinical results from plasma and serum samples
43. 1264P - Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)
44. 1005P - Molecular analysis in serial biopsies in sinonasal mucosal melanoma
45. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.